FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Autolus Therapuetics plc has been granted FDA approval for Aucatzyl (obecabtagene autoleucel) for the treatment of acute lymphoblastic leukemia in adults, becoming the first marketed CAR T therapy ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

The National Labor Relations Board has filed a complaint against Cincinnati-based CommuniCare, a post-acute care network, for allegedly attempting to enforce stay-or-pay employment agreements.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...